Aldosterone as a Possible Contributor to Eye Diseases

Area of Science:

• Ophthalmology
• Endocrinology
• Cardiovascular Research

Background:

• The renin-angiotensin-aldosterone system (RAAS) plays a key role in cardiovascular regulation.
• Aldosterone, a primary effector of RAAS, is gaining attention for its potential involvement in ocular pathologies.
• Primary aldosteronism serves as a model for studying systemic aldosterone excess effects on vision.

Purpose of the Study:

• To explore the role of aldosterone and the RAAS in the pathogenesis of various eye diseases.
• To investigate the potential of targeting aldosterone or its receptors for treating vision-threatening ocular conditions.

Main Methods:

• Reviewing the presence and function of RAAS components within ocular tissues.
• Examining animal models of ocular diseases, including diabetic macular edema, retinal vein occlusion, retinopathy of prematurity, central serous chorioretinopathy, and glaucoma.
• Analyzing evidence linking aldosterone or mineralocorticoid receptor activity to disease exacerbation.

Main Results:

• RAAS components are found in diverse ocular cells and tissues.
• Evidence suggests aldosterone and mineralocorticoid receptors can worsen pathologies in models of diabetic macular edema, retinal vein occlusion, retinopathy of prematurity, central serous chorioretinopathy, and glaucoma.
• Primary aldosteronism is associated with vision loss through conditions like retinal vein occlusion, central serous chorioretinopathy, and potentially glaucoma.

Conclusions:

• Aldosterone and the RAAS are implicated in the development and progression of several eye diseases.
• Further research is required to determine if modulating aldosterone or mineralocorticoid receptors can prevent vision loss in patients.
• Targeting the RAAS presents a potential therapeutic avenue for managing aldosterone-related ocular conditions.